News and Media
MMS Poised for an Innovative Future with Best Clinical Research Organization Award and Two Key Executive Appointments
MMS announced the growth of its leadership team with the appointment of Kelly J. Hill to Executive Vice President (EVP) of Global Business Operations and Strategy and Michelle Gayari to Executive Vice President of Global Operational Excellence and Innovation. This comes as the company was awarded Best Data-Focused Biotech CRO in the International Life Sciences Awards.
Health Data Research UK Selects MMS as Data Services Partner for the International COVID-19 Data Alliance
MMS has been selected by Health Data Research UK (HDR UK) – the national institute for health data science – as a partner to support the International COVID-19 Data Alliance (ICODA) initiative. MMS was selected from a pool of some of the world’s top clinical research organizations to provide data engineering services to support a globally coordinated, health data-led research response to tackle the COVID-19 pandemic.
MMS HOLDINGS JOINS DECENTRALIZED TRIALS & RESEARCH ALLIANCE (DTRA) AS A FOUNDING MEMBER TO ACCELERATE THE ADOPTION OF PATIENT-FOCUSED CLINICAL TRIALS
MMS Holdings – an award-winning, data-focused CRO – joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
MMS Academy Launches Mobile App for Accessing Pharmaceutical Industry Virtual Learning Courses from Anywhere
CANTON, Mich. (October 28, 2020) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that its learning arm, MMS Academy, now offers access to all of its virtual pharmaceutical industry courses through a mobile smart device application. As an innovative convenience, students and working professionals can access course material anytime, anywhere across the globe.
EY Announces Dr. Uma Sharma of MMS Holdings as an Entrepreneur Of The Year® 2020 Michigan and Northwest Ohio Award Finalist
CANTON, Mich. (August 31, 2020) – Ernst & Young LLP (EY US) today announced that Founder and Chief Scientific Officer Uma Sharma, PhD of MMS Holdings was named an Entrepreneur Of The Year® 2020 Michigan and Northwest Ohio Award finalist. Now in its 34th year, the Entrepreneur Of The Year program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world. Uma was selected as one of 29 finalists by a panel of independent judges from a competitive pool of nominations.
CANTON, Mich. (August 28, 2020)– MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today that Uma Sharma, Ph.D., Founder and Chief Scientific Officer of MMS, has been invited to join the board of directors with MichBio – a trade association committed to driving growth in Michigan’s biosciences industry and its many sectors for more than 20 years. Dr. Sharma will serve on the board from August 2020 to December 2021.
Uttar Pradesh, India (August 18, 2020) – MMS Holdings Inc. (MMS) – an award-winning, data-focused and technology-enabled CRO – announced today that Maharana Pratap Group of Institutions (MPGI) has partnered with MMS Academy, the learning arm of MMS. In the collaboration, MPGI students will be able to gain real-world pharmaceutical industry knowledge through an online, assessment-based certification program offered by MMS Academy.
CANTON, Mich. (July 20, 2020) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that it has been recognized by Corporate LiveWire as the Most Innovative Clinical Research Organization (CRO) in the United States.
By Rob DiCicco, June 11, 2020
The novel coronavirus (COVID-19) pandemic is an unprecedented crisis that has galvanized the global scientific community around the search for a viable vaccine and effective therapies. This incredible commitment to science may ultimately pay dividends, but each passing day is critical as we seek to stem the tide of this deadly pandemic. There is a collective sense of urgency to consider incremental ways to expediate the process to get treatments to patients and our IBM® Clinical Development (ICD) solution is designed to help address a challenge such as this.
THUNDER BAY, ONTARIO (June 08, 2020) – IGY Life Sciences today announced it will be collaborating with clinical data and regulatory experts, MMS Holdings (MMS), to further the development of IgY-110, an anti-CoV2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed.
SUBSCRIBE TO UPDATES
Please provide your information below to stay informed.
CONNECT WITH US